NCT05557708View on ClinicalTrials.gov

A Safety Study of 212Pb-Pentixather Radioligand Therapy

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 1, 2026

Primary Completion Date

June 30, 2028

Study Completion Date

June 30, 2030

Conditions
Carcinoid Tumor LungNeuroendocrine Tumor of the LungCarcinoma, Small-Cell Lung
Interventions
DRUG

212-Lead Pentixather

Pentixather radiolabeled with 212-lead to target malignant cells with the CXCR4 ligand.

DIAGNOSTIC_TEST

203-Lead Pentixather SPECT/CT

Pentixather radiolabeled with 203-Lead to identify the CXCR4 ligand on the malignant lesions for dosimetric analysis and treatment planning.

Trial Locations (1)

52242

University of Iowa Health Care, Iowa City

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Cancer Institute (NCI)

NIH

collaborator

Holden Comprehensive Cancer Center

OTHER

lead

Yusuf Menda

OTHER

NCT05557708 - A Safety Study of 212Pb-Pentixather Radioligand Therapy | Biotech Hunter | Biotech Hunter